FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

被引：0
|
作者：
Daneshmand, Siamak
van der Heijden, Michiel S.
Jacob, Joseph M.
Necchi, Andrea
Xylinas, Evanguelos
Morris, David S.
Spiegelhalder, Philip
Zainfeld, Daniel
Kang, Taek Won
Matulay, Justin T.
Belkoff, Laurence H.
Decaestecker, Karel
Arentsen, Harm
Hampras, Shalaka
Jin, Shu
Cutie, Christopher J.
Sweiti, Hussein
Stromberg, Katherine
Martin, Jason
Simone, Giuseppe
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
LBA02-03
引用
收藏
页码：E1187 / E1187
页数：1
相关论文
共 50 条
  • [41] Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study
    Miguel Ángel Arrabal Polo
    María Teresa Melgarejo Segura
    Yaiza Yáñez Castillo
    Ana Morales Martínez
    Manuel Pareja Vílchez
    Miguel Arrabal Martín
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7453 - 7459
  • [42] Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study
    Polo, Miguel Angel Arrabal
    Segura, Maria Teresa Melgarejo
    Castillo, Yaiza Yanez
    Martinez, Ana Morales
    Vilchez, Manuel Pareja
    Martin, Miguel Arrabal
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7453 - 7459
  • [43] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    EUROPEAN UROLOGY, 2023, 83 : S748 - S748
  • [44] Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024
    Qu, Feng
    Darji, Saloni
    Thompson, David H.
    PHARMACEUTICS, 2024, 16 (09)
  • [45] Predictors and prognostic implications of clinical decisions in patients with primary high-risk non-muscle-invasive bladder cancer - results of a cross country retrospective study
    Poletajew, S.
    Biernacki, R.
    Buraczynski, P.
    Chojnacki, J.
    Czarniecki, S.
    Gajewska, D.
    Pohaba, T.
    Sondka-Migdalska, J.
    Skrzypczyk, M.
    Suchojad, T.
    Wojtkowiak, D.
    Zaforemski, B.
    Zapala, L.
    Zemla, A.
    Radziszewski, P.
    NEOPLASMA, 2018, 65 (01) : 147 - 152
  • [46] PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guérin (BCG) Therapy
    Maas, Moritz
    Hilsendecker, Andreas
    Pertoll, Alexandra
    Stuehler, Viktoria
    Walz, Simon
    Rausch, Steffen
    Stenzl, Arnulf
    Tsaur, Igor
    Hennenlotter, Joerg
    Aufderklamm, Stefan
    CANCERS, 2024, 16 (07)
  • [47] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    Balar, Arjun, V
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    LANCET ONCOLOGY, 2021, 22 (07): : 919 - 930
  • [48] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
    De Santis, Maria
    Abdrashitov, Ramil
    Hegele, Axel
    Kolb, Margaret
    Parker, Suzanne
    Redorta, Juan Palou
    Nishiyama, Hiroyuki
    Xiao, Feng
    Gupta, Ashok Kumar
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [49] A phase 3, randomized, open-label, multicenter, global study of Durvalumab and bacillus calmette-Guerin (BCG) vs BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)
    Boegemann, M.
    Abdrashitov, R.
    Casuscelli, J.
    Feyerabend, S.
    Hatiboglu, G.
    Hegele, A.
    Hellmis, E.
    Klier, J.
    von Klot, C.
    Schmitz-Draeger, B.
    Spiegelhalder, P.
    Stagge, E.
    De Santis, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 105 - 105
  • [50] Pathologic T1 substaging improves the identification of high-risk non-muscle invasive bladder cancer patients at risk of BCG failure.
    de Jong, Florus C.
    Hoedemaeker, Robert F.
    Mensink, Jolien T. M.
    Kvikstad, Vebjorn
    Boeve, Egbert R.
    van der Schoot, Deric K. E.
    Zwarthoff, Ellen C.
    Zuiverloon, Tahlita C. M.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 49 - 50
12345